PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
29110619-6	2018	RESULT: The addition of phenylbutazone, a marker for the HSA drug-binding site I, leads to displacement of CAPIDAN from this site due to direct competition between phenylbutazone and the dye.	Phenylbutazone	24-38	albumin	Homo sapiens	57-60
30241420-5	2018	It was found that the oxidation of HSA by Tau-NBr2, but not by Tau-NHCl, provoked a significant increase in the association constant with phenylbutazone.	Phenylbutazone	138-152	neighbor of BRCA1 lncRNA 2	Homo sapiens	46-50
30094858-8	2018	Glandular gastric ulceration scores and fecal MPO concentrations were higher in horses treated with phenylbutazone at day 10 (P < .001 and P = .0018, respectively).	Phenylbutazone	100-114	myeloperoxidase	Equus caballus	46-49
30094858-9	2018	Increases in fecal MPO were significantly decreased 10 days following cessation of treatment for firocoxib but remained greater than baseline for the phenylbutazone group.	Phenylbutazone	150-164	myeloperoxidase	Equus caballus	19-22
32054946-3	2020	We previously reported that a nonsteroidal anti-inflammatory drug (NSAID), phenylbutazone, upregulates MBNL1 expression in DM1 mouse model by demethylation of MeR2, an enhancer element in Mbnl1 intron 1.	Phenylbutazone	75-89	muscleblind like splicing factor 1	Mus musculus	103-108
32054946-3	2020	We previously reported that a nonsteroidal anti-inflammatory drug (NSAID), phenylbutazone, upregulates MBNL1 expression in DM1 mouse model by demethylation of MeR2, an enhancer element in Mbnl1 intron 1.	Phenylbutazone	75-89	muscleblind like splicing factor 1	Mus musculus	188-193
31100401-0	2019	Role of Herborn (K240E) and Milano Slow (D375H) human serum albumin variants towards binding of phenylbutazone and ibuprofen.	Phenylbutazone	96-110	albumin	Homo sapiens	54-67
31100401-5	2019	In the present study, we have aimed to understand the effect of two natural variants of HSA, such as Herborn (K240E) and Milano Slow (D375H) on the binding of phenylbutazone and ibuprofen.	Phenylbutazone	159-173	albumin	Homo sapiens	88-91
31100401-8	2019	The interaction of HSA and its variants to phenylbutazone and ibuprofen was studied using fluorescence spectroscopy.	Phenylbutazone	43-57	albumin	Homo sapiens	19-22
29110619-6	2018	RESULT: The addition of phenylbutazone, a marker for the HSA drug-binding site I, leads to displacement of CAPIDAN from this site due to direct competition between phenylbutazone and the dye.	Phenylbutazone	164-178	albumin	Homo sapiens	57-60
26524404-9	2016	The cytotoxic effects of pre-incubated human IAPP on cultured INS-1 cells were noticeably reduced in the presence of diclofenac, meloxicam, phenylbutazone, sulindac, and tenoxicam at a molar ratio of 1:10.	Phenylbutazone	140-154	islet amyloid polypeptide	Homo sapiens	45-49
27126921-0	2016	Phenylbutazone induces expression of MBNL1 and suppresses formation of MBNL1-CUG RNA foci in a mouse model of myotonic dystrophy.	Phenylbutazone	0-14	muscleblind like splicing factor 1	Mus musculus	37-42
27126921-0	2016	Phenylbutazone induces expression of MBNL1 and suppresses formation of MBNL1-CUG RNA foci in a mouse model of myotonic dystrophy.	Phenylbutazone	0-14	muscleblind like splicing factor 1	Mus musculus	71-76
27126921-5	2016	In this study, we found that a nonsteroidal anti-inflammatory drug (NSAID), phenylbutazone (PBZ), upregulated the expression of MBNL1 in C2C12 myoblasts as well as in the HSA(LR) mouse model for DM1.	Phenylbutazone	76-90	muscleblind like splicing factor 1	Mus musculus	128-133
27126921-5	2016	In this study, we found that a nonsteroidal anti-inflammatory drug (NSAID), phenylbutazone (PBZ), upregulated the expression of MBNL1 in C2C12 myoblasts as well as in the HSA(LR) mouse model for DM1.	Phenylbutazone	92-95	muscleblind like splicing factor 1	Mus musculus	128-133
27126921-6	2016	In the DM1 mice model, PBZ ameliorated aberrant splicing of Clcn1, Nfix, and Rpn2.	Phenylbutazone	23-26	chloride channel, voltage-sensitive 1	Mus musculus	60-65
27126921-6	2016	In the DM1 mice model, PBZ ameliorated aberrant splicing of Clcn1, Nfix, and Rpn2.	Phenylbutazone	23-26	nuclear factor I/X	Mus musculus	67-71
27126921-6	2016	In the DM1 mice model, PBZ ameliorated aberrant splicing of Clcn1, Nfix, and Rpn2.	Phenylbutazone	23-26	ribophorin II	Mus musculus	77-81
27126921-9	2016	First, PBZ suppressed methylation of an enhancer region in Mbnl1 intron 1, and enhanced transcription of Mbnl1 mRNA.	Phenylbutazone	7-10	muscleblind like splicing factor 1	Mus musculus	59-64
27126921-9	2016	First, PBZ suppressed methylation of an enhancer region in Mbnl1 intron 1, and enhanced transcription of Mbnl1 mRNA.	Phenylbutazone	7-10	muscleblind like splicing factor 1	Mus musculus	105-110
27126921-10	2016	Second, PBZ attenuated binding of MBNL1 to abnormally expanded CUG repeats in cellulo and in vitro.	Phenylbutazone	8-11	muscleblind like splicing factor 1	Mus musculus	34-39
27126921-11	2016	Our studies suggest that PBZ is a potent therapeutic agent for DM1 that upregulates availability of MBNL1.	Phenylbutazone	25-28	muscleblind like splicing factor 1	Mus musculus	100-105
22691166-10	2012	Finally, measurement of PTN protein expression in the GI tract of horses treated with phenylbutazone showed that PTN expression is reduced by NSAIDs in vivo.	Phenylbutazone	86-100	pleiotrophin	Equus caballus	24-27
25054206-6	2015	Consequently, inference drawn from the site-specific markers (phenylbutazone, site I marker) studies to identify the binding site of HSA noticed that piperine binds at site I (IIA), which was further authenticated by molecular docking and molecular dynamic (MD) studies.	Phenylbutazone	62-76	CD24a antigen	Mus musculus	133-136
25854527-5	2015	Phenylbutazone and carvacrol (UGT1A6 and UGT1A9 chemical inhibitors, respectively) at different concentrations (50, 100, and 200 muM) significantly inhibited the formation of glucuronidates of ET and 4-ME in HLM, UGT1A6, and UGT1A9 when the concentrations of ET and 4-ME ranged from 10 to 300 muM (P < 0.05).	Phenylbutazone	0-14	UDP glucuronosyltransferase family 1 member A6	Homo sapiens	30-36
25854527-5	2015	Phenylbutazone and carvacrol (UGT1A6 and UGT1A9 chemical inhibitors, respectively) at different concentrations (50, 100, and 200 muM) significantly inhibited the formation of glucuronidates of ET and 4-ME in HLM, UGT1A6, and UGT1A9 when the concentrations of ET and 4-ME ranged from 10 to 300 muM (P < 0.05).	Phenylbutazone	0-14	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	41-47
25854527-5	2015	Phenylbutazone and carvacrol (UGT1A6 and UGT1A9 chemical inhibitors, respectively) at different concentrations (50, 100, and 200 muM) significantly inhibited the formation of glucuronidates of ET and 4-ME in HLM, UGT1A6, and UGT1A9 when the concentrations of ET and 4-ME ranged from 10 to 300 muM (P < 0.05).	Phenylbutazone	0-14	UDP glucuronosyltransferase family 1 member A6	Homo sapiens	213-219
25854527-5	2015	Phenylbutazone and carvacrol (UGT1A6 and UGT1A9 chemical inhibitors, respectively) at different concentrations (50, 100, and 200 muM) significantly inhibited the formation of glucuronidates of ET and 4-ME in HLM, UGT1A6, and UGT1A9 when the concentrations of ET and 4-ME ranged from 10 to 300 muM (P < 0.05).	Phenylbutazone	0-14	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	225-231
25809983-7	2015	SLC5A6-mediated transport in hCMEC/D3 was markedly inhibited not only by biotin and pantothenic acid, but also by prostaglandin E2, lipoic acid, docosahexaenoic acid, indomethacin, ketoprofen, diclofenac, ibuprofen, phenylbutazone, and flurbiprofen.	Phenylbutazone	216-230	solute carrier family 5 member 6	Homo sapiens	0-6
23996546-5	2014	The bergenin glucuronosyltransferase activities in HLMs and UGT1A1 were inhibited by phenylbutazone, estradiol and bilirubin.	Phenylbutazone	85-99	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	60-66
22691166-10	2012	Finally, measurement of PTN protein expression in the GI tract of horses treated with phenylbutazone showed that PTN expression is reduced by NSAIDs in vivo.	Phenylbutazone	86-100	pleiotrophin	Equus caballus	113-116
22204294-0	2012	Effects of phenylbutazone on gene expression of cyclooxygenase-1 and -2 in the oral, glandular gastric, and bladder mucosae of healthy horses.	Phenylbutazone	11-25	prostaglandin-endoperoxide synthase 1	Equus caballus	48-71
21856214-10	2011	The decrease of K(aII) values suggests that the competition between PBZ and ASA in binding to serum albumin in the second class of binding sites occurs.	Phenylbutazone	68-71	albumin	Homo sapiens	94-107
22572482-7	2012	The chemical inhibition study showed that the IC(50) for phenylbutazone inhibition of Sal A glucuronidation was 50.3 +- 4.3 and 39.4 +- 2.9 microM by HLMs and UGT1A9, respectively.	Phenylbutazone	57-71	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	159-165
21856214-0	2011	A spectroscopic study of phenylbutazone and aspirin bound to serum albumin in rheumatoid diseases.	Phenylbutazone	25-39	albumin	Homo sapiens	61-74
21856214-4	2011	Using fluorescence spectroscopy the location of binding site in serum albumin (SA) for PBZ and ASA was found.	Phenylbutazone	87-90	albumin	Homo sapiens	64-77
21856214-6	2011	PBZ and ASA change the affinity of each other to the binding site in serum albumin (SA).	Phenylbutazone	0-3	albumin	Homo sapiens	69-82
20375181-8	2010	Finally, experiments conducted to inhibit the glucuronosyltransferase activity in the human liver microsomes assay showed that phenylbutazone, trifluoperazine, propofol, and 1-naphthol effectively inhibited CA-4 glucuronidation.	Phenylbutazone	127-141	carbonic anhydrase 4	Homo sapiens	207-211
19182419-4	2009	In an analogous way, the competitive relations were observed between EGCG and the site-I- (PB and TB) and site-II-binding (ethacrynic acid, EA) drugs for the binding of EGCG and BSA.	Phenylbutazone	91-93	albumin	Homo sapiens	178-181
20429273-15	2010	The competition of K-35 with phenylbutazone, a marker of the albumin drug-binding site I, allows one to suggest that the K-35 site of the first type is localized near the drug site I, while the sites of the second and third types are close to it.	Phenylbutazone	29-43	keratin 35	Homo sapiens	121-125
19615934-0	2009	Interaction of phenylbutazone and colchicine in binding to serum albumin in rheumatoid therapy: 1H NMR study.	Phenylbutazone	15-29	albumin	Homo sapiens	59-72
19615934-5	2009	Interaction of phenylbutazone and colchicine in binding to serum albumin and competition between them in gout has been studied by proton nuclear magnetic resonance ((1)H NMR) technique.	Phenylbutazone	15-29	albumin	Homo sapiens	59-72
19615934-7	2009	The study of competition between phenylbutazone and colchicine in binding to serum albumin points to the change of their affinity to serum albumin in the ternary systems.	Phenylbutazone	33-47	albumin	Homo sapiens	77-90
19615934-7	2009	The study of competition between phenylbutazone and colchicine in binding to serum albumin points to the change of their affinity to serum albumin in the ternary systems.	Phenylbutazone	33-47	albumin	Homo sapiens	133-146
17499219-5	2007	Treatment of IEC-6 and IEC-Cdx2 cells with indomethacin, phenylbutazone and NS-398 induced significant depolarization of E(m), whereas treatment with SC-560 had no effect on E(m).	Phenylbutazone	57-71	caudal type homeo box 2	Rattus norvegicus	27-31
18765282-2	2008	Model drug compounds selected were cinnarizine (CIN), itraconazole (ITR) and phenylbutazone (PHB) as they showed a decrease in dissolution rate upon spray-drying in the absence of additional matrix formers, yielding release values after 5min of dissolution (release(5min)) of 57.7+/-1.0% (CIN), 56.3+/-3.8% (ITR) and 67.4+/-1.3% (PHB).	Phenylbutazone	77-91	pyridoxal phosphatase	Homo sapiens	289-292
18602884-0	2008	Amino acid positions 69-132 of UGT1A9 are involved in the C-glucuronidation of phenylbutazone.	Phenylbutazone	79-93	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	31-37
18765282-2	2008	Model drug compounds selected were cinnarizine (CIN), itraconazole (ITR) and phenylbutazone (PHB) as they showed a decrease in dissolution rate upon spray-drying in the absence of additional matrix formers, yielding release values after 5min of dissolution (release(5min)) of 57.7+/-1.0% (CIN), 56.3+/-3.8% (ITR) and 67.4+/-1.3% (PHB).	Phenylbutazone	93-96	pyridoxal phosphatase	Homo sapiens	289-292
18541222-8	2008	Consistent with these observations, the UGT1A selective inhibitors phenylbutazone and sulfinpyrazone decreased FSMG formation by HLM, HKCM and HKMM by 60-80%, whereas the UGT2B7 selective inhibitor fluconazole reduced FSM glucuronidation by < or =20%.	Phenylbutazone	67-81	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	40-45
17499219-3	2007	Epithelial cell migration in response to the wounding of confluent IEC-6 and IEC-Cdx2 monolayers was reduced by indomethacin (100 microM), phenylbutazone (100 microM) and NS-398 (100 microM) but not by SC-560 (1 microM).	Phenylbutazone	139-153	caudal type homeo box 2	Rattus norvegicus	81-85
17328244-7	2007	Aspirin and phenylbutazone also dose-dependently attenuated CD4+ T cell proliferation stimulated by concanavalin A (Con A) and CD8+ CTLL-2 cell proliferation induced by interleukin (IL)-2.	Phenylbutazone	12-26	interleukin 2	Mus musculus	169-187
17269876-12	2007	Increased osteocalcin concentration may indicate an undetermined anabolic effect of phenylbutazone administration on periarticular bone or transient induction of osteogenesis in articular chondrocytes or a mesenchymal subpopulation of synoviocytes.	Phenylbutazone	84-98	osteocalcin	Equus caballus	10-21
17315542-13	2006	The formation of DRF-6574 glucuronide by human liver, intestinal and UGT1A1, 1A3 and 1A8 microsomes was effectively inhibited by phenylbutazone.	Phenylbutazone	129-143	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	69-75
16949544-0	2006	Identification of human UDP-glucuronosyltransferase isoform(s) responsible for the C-glucuronidation of phenylbutazone.	Phenylbutazone	104-118	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	24-51
16949544-6	2006	Human liver and kidney microsomes, which are well known to express UGT1A9, had C-glucuronidating activity toward PB.	Phenylbutazone	113-115	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	67-73
17005917-10	2007	Phenylbutazone stimulated MRP2 and celecoxib MRP4 transport at low concentrations and inhibited both transporters at high concentration.	Phenylbutazone	0-14	ATP binding cassette subfamily C member 2	Homo sapiens	26-30
17005917-10	2007	Phenylbutazone stimulated MRP2 and celecoxib MRP4 transport at low concentrations and inhibited both transporters at high concentration.	Phenylbutazone	0-14	ATP binding cassette subfamily C member 4	Homo sapiens	45-49
16380352-3	2005	Oral administration of either PLH and PLM at a dose of 300 mg/kg body weight showed statistically significant (p < 0.001) inhibition of rat paw edema by 41.09% and 30.15%, respectively, which was comparable to that of standard drug phenylbutazone (42.15%).	Phenylbutazone	235-249	phospholamban	Rattus norvegicus	38-41
15939622-0	2005	COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis.	Phenylbutazone	45-59	cytochrome c oxidase subunit I	Equus caballus	0-5
12171167-4	2002	Northern blot analysis was used to quantify the expression of COX-2 in first-passage cultures of equine articular chondrocytes propagated in media containing dexamethasone (DEX), phenylbutazone (PBZ), polysulfated glycosaminoglycan, and hyaluronan, each at concentrations of 10 and 100 microg/ml and each with or without reIL-1beta.	Phenylbutazone	179-193	cytochrome c oxidase subunit II	Equus caballus	62-67
15939622-0	2005	COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis.	Phenylbutazone	45-59	cytochrome c oxidase subunit II	Equus caballus	10-15
15939622-3	2005	However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater COX-2 selectivity than at IC50, and meloxicam (-41.2%) and carprofen (-12.9%) had lower COX-2 selectivity than at IC50.	Phenylbutazone	17-31	cytochrome c oxidase subunit II	Equus caballus	76-81
15939622-3	2005	However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater COX-2 selectivity than at IC50, and meloxicam (-41.2%) and carprofen (-12.9%) had lower COX-2 selectivity than at IC50.	Phenylbutazone	17-31	cytochrome c oxidase subunit II	Equus caballus	164-169
12602591-6	2003	RESULTS: Flunixin meglumine and phenylbutazone were selective inhibitors of COX-1.	Phenylbutazone	32-46	cytochrome c oxidase I, mitochondrial	Mus musculus	76-81
12705172-1	2003	This study deals with the competitive interactions of sulindac (CAS 38194-50-2) with specific markers for the major binding areas on human serum albumin (HSA): phenylbutazone (CAS 50-33-9) and warfarin (CAS 129-06-6) for Site I, and diazepam (CAS 439-14-5) for Site II.	Phenylbutazone	160-174	albumin	Homo sapiens	139-152
15563928-8	2005	In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable COX-1 prostanoid TXB2 was significantly reduced by phenylbutazone (P<0.05), but not etodolac.	Phenylbutazone	171-185	cytochrome c oxidase subunit I	Equus caballus	120-125
12602591-1	2003	OBJECTIVE: To determine whether the nonsteroidal anti-inflammatory drugs (NSAIDs) carprofen, flunixin meglumine, and phenylbutazone have cyclooxygenase (COX)-independent effects that specifically inhibit activation of the proinflammatory transcription factor nuclear factor kappa B (NfkappaB).	Phenylbutazone	117-131	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	259-281
12602591-1	2003	OBJECTIVE: To determine whether the nonsteroidal anti-inflammatory drugs (NSAIDs) carprofen, flunixin meglumine, and phenylbutazone have cyclooxygenase (COX)-independent effects that specifically inhibit activation of the proinflammatory transcription factor nuclear factor kappa B (NfkappaB).	Phenylbutazone	117-131	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	283-291
12171167-4	2002	Northern blot analysis was used to quantify the expression of COX-2 in first-passage cultures of equine articular chondrocytes propagated in media containing dexamethasone (DEX), phenylbutazone (PBZ), polysulfated glycosaminoglycan, and hyaluronan, each at concentrations of 10 and 100 microg/ml and each with or without reIL-1beta.	Phenylbutazone	195-198	cytochrome c oxidase subunit II	Equus caballus	62-67
12130730-7	2002	The K(i) values for the effects of salicylate, phenylbutazone, indomethacin, and probenecid on hOAT3-mediated methotrexate uptake were comparable with therapeutically relevant plasma concentrations of unbound drugs.	Phenylbutazone	47-61	solute carrier family 22 member 8	Homo sapiens	95-100
12130730-11	2002	Furthermore, it was predicted that hOAT3 is the site of drug interactions between methotrexate and salicylate, phenylbutazone, indomethacin, and probenecid in vivo.	Phenylbutazone	111-125	solute carrier family 22 member 8	Homo sapiens	35-40
11763181-1	2001	OBJECTIVE: To evaluate the effects of orally administered phenylbutazone on proteoglycan synthesis and chondrocyte inhibition by IL-1beta in articular cartilage explants of horses.	Phenylbutazone	58-72	interleukin-1 beta	Equus caballus	129-137
12118680-7	2002	Similarly, pretreatment with phenylbutazone, followed by exposure to relL-1beta and PGE2 (5 mg/ml), was associated with a reduced expression of the genes of interest, an effect that was significant for MMP 1, MMP 13, and TIMP 1.	Phenylbutazone	29-43	MMP-1	Equus caballus	202-207
12118680-7	2002	Similarly, pretreatment with phenylbutazone, followed by exposure to relL-1beta and PGE2 (5 mg/ml), was associated with a reduced expression of the genes of interest, an effect that was significant for MMP 1, MMP 13, and TIMP 1.	Phenylbutazone	29-43	matrix metallopeptidase 13	Equus caballus	209-215
12118680-7	2002	Similarly, pretreatment with phenylbutazone, followed by exposure to relL-1beta and PGE2 (5 mg/ml), was associated with a reduced expression of the genes of interest, an effect that was significant for MMP 1, MMP 13, and TIMP 1.	Phenylbutazone	29-43	TIMP metallopeptidase inhibitor 1	Equus caballus	221-227
11763181-10	2001	CONCLUSIONS AND CLINICAL RELEVANCE: Oral administration of phenylbutazone for 14 days significantly decreased proteoglycan synthesis in articular culture explants from healthy horses to a degree similar to that induced by in vitro exposure to IL-1beta.	Phenylbutazone	59-73	interleukin-1 beta	Equus caballus	243-251
10219967-9	1999	Induction of CYP3A4-dependent reporter gene expression and enhancement of the induction by the glucocorticoid receptor was also observed with pregnenolone-16alpha-carbonitrile (PCN), rifampicin, phenytoin, carbamazepine, phenylbutazone and phenobarbitone, all known in vivo inducers of CYP3A4 in man.	Phenylbutazone	221-235	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-19
10462056-3	1999	Attempts were made to characterize its binding site using as competitors warfarin, phenylbutazone and diazepam, which bind in a specific site or region on the HSA.	Phenylbutazone	83-97	albumin	Homo sapiens	159-162
11703020-8	2001	In contrast, NSAID such as phenylbutazone and flunixin meglumine were more potent inhibitors of COX-1 than COX-2 in canine and equine blood.	Phenylbutazone	27-41	cytochrome c oxidase subunit I	Canis lupus familiaris	96-101
11703020-8	2001	In contrast, NSAID such as phenylbutazone and flunixin meglumine were more potent inhibitors of COX-1 than COX-2 in canine and equine blood.	Phenylbutazone	27-41	cytochrome c oxidase subunit II	Canis lupus familiaris	107-112
10416217-7	1999	The rank order of cytotoxicity observed in hMIC was phenylbutazone > mefenamic acid > aspirin > paracetamol.	Phenylbutazone	52-66	mannosidase alpha class 1C member 1	Homo sapiens	43-47
10219470-0	1999	Binding of phenylbutazone to human serum albumin.	Phenylbutazone	11-25	albumin	Homo sapiens	35-48
10219470-2	1999	The quantitative parameters characterizing the binding of phenylbutazone (CAS 50-33-9) to human serum albumin are determined using the circular dichroism titration method and a combined mathematical approach.	Phenylbutazone	58-72	albumin	Homo sapiens	96-109
10219967-9	1999	Induction of CYP3A4-dependent reporter gene expression and enhancement of the induction by the glucocorticoid receptor was also observed with pregnenolone-16alpha-carbonitrile (PCN), rifampicin, phenytoin, carbamazepine, phenylbutazone and phenobarbitone, all known in vivo inducers of CYP3A4 in man.	Phenylbutazone	221-235	nuclear receptor subfamily 3 group C member 1	Homo sapiens	95-118
10030127-1	1999	The purposes of this study were: (1) to investigate which arachidonic acid metabolites contributed to platelet-activating factor (PAF) induced pulmonary dysfunction; and (2) to compare the effect of two non-steroidal anti-inflammatory drugs, phenylbutazone and ketoprofen in a model of PAF-induced reversible lung inflammation in six calves.	Phenylbutazone	242-256	PCNA-associated factor	Bos taurus	130-133
10030127-2	1999	In placebo and phenylbutazone groups, PAF infusion induced significant dysfunctions in the pattern of breathing, mechanics of breathing and gas exchange.	Phenylbutazone	15-29	PCNA-associated factor	Bos taurus	38-41
10030127-0	1999	Ketoprofen and phenylbutazone attenuation of PAF-induced lung inflammation in calves.	Phenylbutazone	15-29	PCNA-associated factor	Bos taurus	45-48
22556860-5	1998	Acid phosphatase, GPT and GOT activities were significantly reduced by Balarishta, Dhanvantara gutika and phenyl butazone in liver.	Phenylbutazone	106-121	glutamic--pyruvic transaminase	Rattus norvegicus	18-21
9675607-7	1998	Phenylbutazone and FM have distinct effects on carrageenan-induced cyclooxygenase (COX-2) and platelet COX (COX-1).	Phenylbutazone	0-14	cytochrome c oxidase subunit I	Ovis aries	83-86
9675607-7	1998	Phenylbutazone and FM have distinct effects on carrageenan-induced cyclooxygenase (COX-2) and platelet COX (COX-1).	Phenylbutazone	0-14	cytochrome c oxidase subunit I	Ovis aries	108-113
9675607-7	1998	Phenylbutazone and FM have distinct effects on carrageenan-induced cyclooxygenase (COX-2) and platelet COX (COX-1).	Phenylbutazone	0-14	cytochrome c oxidase subunit II	Ovis aries	83-88
9728323-16	1998	The relaxation by naproxen, phenylbutazone, piroxicam and tolmetin is presumably produced by increasing cAMP because the effects of these are antagonized with Rp-cAMPS and H-7, and by pertussis-toxin-sensitive mechanisms.	Phenylbutazone	28-42	calmodulin 2, pseudogene 1	Rattus norvegicus	162-167
9728323-16	1998	The relaxation by naproxen, phenylbutazone, piroxicam and tolmetin is presumably produced by increasing cAMP because the effects of these are antagonized with Rp-cAMPS and H-7, and by pertussis-toxin-sensitive mechanisms.	Phenylbutazone	28-42	solute carrier family 9 member A2	Rattus norvegicus	172-175
9728323-8	1998	The relaxant effects of naproxen, phenylbutazone, piroxicam and tolmetin were significantly antagonized with pertussis toxin (50 ng ml-1), Rp-cAMPS (100 microM) and H-7 (1 microM).	Phenylbutazone	34-48	calmodulin 2, pseudogene 1	Rattus norvegicus	142-147
9728323-8	1998	The relaxant effects of naproxen, phenylbutazone, piroxicam and tolmetin were significantly antagonized with pertussis toxin (50 ng ml-1), Rp-cAMPS (100 microM) and H-7 (1 microM).	Phenylbutazone	34-48	solute carrier family 9 member A2	Rattus norvegicus	165-168
7564880-5	1995	However, indomethacin, diclofenac, phenylbutazone, mefenamic acid, naproxen, piroxicam, aspirin and W-7 inhibit, in a concentration-dependent way, the calmodulin-stimulated activity of phosphodiesterase.	Phenylbutazone	35-49	calmodulin 1	Rattus norvegicus	151-161
9704200-3	1998	Phenylbutazone delayed the postoperative rise of fibrinogen concentration and reduced the plasminogen level on the first day after surgery.	Phenylbutazone	0-14	fibrinogen beta chain	Homo sapiens	49-59
9112701-4	1996	Prolidase activity was measured in cultured human skin fibroblasts, treated with some non-steroid antiinflammatory drugs (acetyl-salicylic acid, sodium salicylate, phenylbutazone, indometacin).	Phenylbutazone	164-178	peptidase D	Homo sapiens	0-9
8660395-5	1995	Arachidonic acid peroxidation was accentuated in a dose-dependent manner and in the presence of haem proteins and H2O2, phenylbutazone also causes inactivation of alpha 1-antiproteinase, a major serine proteinase inhibitor in biological fluids.	Phenylbutazone	120-134	serpin family A member 1	Homo sapiens	163-185
7606814-2	1995	It is known that binding site I on human serum albumin (HSA) consists of a zone of two overlapping regions: the specific binding region represented by warfarin binding and the specific binding region represented by azapropazone and phenylbutazone binding.	Phenylbutazone	232-246	albumin	Homo sapiens	41-54
7703973-3	1994	The induced ellipticities of phenylbutazone, flufenamic acid and ibuprofen-G-BSA complexes diminished and those of warfarin complex were enhanced in comparison with those for the intact bovine serum albumin (BSA) complexes.	Phenylbutazone	29-43	albumin	Homo sapiens	77-80
7811298-6	1994	Phenylbutazone, meclofenamic acid and flufenamic acid could also cause damage to proteins (as measured by inactivation of alpha 1-antiproteinase) in the presence of myoglobin and H2O2.	Phenylbutazone	0-14	serpin family A member 1	Homo sapiens	122-144
7811298-6	1994	Phenylbutazone, meclofenamic acid and flufenamic acid could also cause damage to proteins (as measured by inactivation of alpha 1-antiproteinase) in the presence of myoglobin and H2O2.	Phenylbutazone	0-14	myoglobin	Homo sapiens	165-174
7811298-9	1994	However, only phenylbutazone caused inactivation of alpha 1-antiproteinase in the presence of cytochrome c and H2O2.	Phenylbutazone	14-28	serpin family A member 1	Homo sapiens	52-74
7811298-9	1994	However, only phenylbutazone caused inactivation of alpha 1-antiproteinase in the presence of cytochrome c and H2O2.	Phenylbutazone	14-28	cytochrome c, somatic	Homo sapiens	94-106
7983601-1	1994	The binding of naproxen, ketoprofen, phenylbutazone, salicylic acid, azapropazone, and indobufen to bovine serum albumin was studied by applying the potentiometric ion probe technique.	Phenylbutazone	37-51	albumin	Homo sapiens	107-120
8110026-7	1993	Continued treatment for one week with phenylbutazone (15 mg/kg, BID) resulted in plasma concentrations with wide fluctuations between doses, but the concentration in the exudate remained at a constant level.	Phenylbutazone	38-52	BH3 interacting domain death agonist	Canis lupus familiaris	64-67
1814850-4	1991	Aspirin, ibuprofen, and phenylbutazone also inhibited IL-6 production by adherent cells stimulated with lipopolysaccharide (LPS).	Phenylbutazone	24-38	interleukin 6	Homo sapiens	54-58
8262580-3	1993	Of the non-steroidal anti-inflammatory drugs tested, phenylbutazone was found to be most potent inhibitor of cathepsin L activity.	Phenylbutazone	53-67	cathepsin L1	Capra hircus	109-120
8262580-5	1993	The inhibition by phenylbutazone was of non-competitive type, with a ki of 1.3 x 10(-3) M. Flufenamic acid and indomethacin were also inhibitory to cathepsin L activity, giving half maximal inhibitions at 3.5 mM and 4.5 mM concentrations respectively.	Phenylbutazone	18-32	cathepsin L1	Capra hircus	148-159
8216610-1	1993	Both phenylbutazon and mofebutazon inhibit oxidative fragmentation of the methionine derivative, 2-keto-4-methylthio-butyric acid (KMB) by xanthine oxidase--or diaphorase mediated OH radical production.	Phenylbutazone	5-18	dihydrolipoamide dehydrogenase	Homo sapiens	160-170
1530664-0	1992	Oxidative damage to lipids and alpha 1-antiproteinase by phenylbutazone in the presence of haem proteins: protection by ascorbic acid.	Phenylbutazone	57-71	serpin family A member 1	Rattus norvegicus	31-53
8148809-5	1994	The induced ellipticities of the complexes of ibuprofen, flufenamic acid and phenyl butazone with G-HSA were diminished in comparison with those with HSA.	Phenylbutazone	77-92	albumin	Homo sapiens	100-103
8148809-5	1994	The induced ellipticities of the complexes of ibuprofen, flufenamic acid and phenyl butazone with G-HSA were diminished in comparison with those with HSA.	Phenylbutazone	77-92	albumin	Homo sapiens	150-153
2610712-3	1989	Phenylbutazone, oxyphenbutazone, sulfinpyrazone and diclofenac-sodium proved to be the most efficient inhibitors of elastase and cathepsin G.	Phenylbutazone	0-14	cathepsin G	Homo sapiens	129-140
2351129-2	1990	The data of the present study revealed the ability of various commonly used anti-inflammatory drugs to alter the activity of this enzyme system, where all the tested drugs, namely phenyl butazone, ketoprofen, piroxicam, and acetaminophen, caused an increase in both the activity of aryl hydrocarbon hydroxylase and the cytochrome P450 content whether administered as a single dose or as a repeated dose for 6 consecutive days.	Phenylbutazone	180-195	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	282-310
2157034-6	1990	The non-steroidal anti-inflammatory drugs, phenylbutazone, salicylic acid, aspirin, sodium salicylate in addition to D-penicillamine and dimethylsulfoxide caused dose-dependent inhibition of the cytochrome-c reduction when the cells were stimulated by PMA.	Phenylbutazone	43-57	cytochrome c, somatic	Equus caballus	195-207
2323804-7	1990	Migration of A- and N-PMNs towards C5a was inhibited (P less than 0.001) by preincubation with either a steroidal (122 microM flumethasone) or nonsteroidal (3.3 microM phenylbutazone) antiinflammatory drug.	Phenylbutazone	168-182	complement C5a receptor 1	Homo sapiens	35-38
2632068-0	1989	Binding position of phenylbutazone with bovine serum albumin determined by measuring nuclear magnetic resonance relaxation time.	Phenylbutazone	20-34	albumin	Homo sapiens	47-60
2632068-1	1989	The binding of phenylbutazone (PB) to bovine serum albumin (BSA) was considered to be predominantly due to hydrophobic interaction based on the thermodynamic parameters obtained by an equilibrium dialysis method.	Phenylbutazone	15-29	albumin	Homo sapiens	45-64
2632068-1	1989	The binding of phenylbutazone (PB) to bovine serum albumin (BSA) was considered to be predominantly due to hydrophobic interaction based on the thermodynamic parameters obtained by an equilibrium dialysis method.	Phenylbutazone	31-33	albumin	Homo sapiens	45-64
2632068-4	1989	The spin-lattice relaxation time (T1) of PB was almost concentration-independent, but decreased in the presence of BSA to 36-38% for the phenyl group and 48-100% for the butyl group.	Phenylbutazone	41-43	albumin	Homo sapiens	115-118
2632068-5	1989	The spin-spin relaxation time (T2) of PB was also almost independent of concentration, but was remarkably decreased in the presence of BSA to ca.	Phenylbutazone	38-40	albumin	Homo sapiens	135-138
2632068-11	1989	The binding of PB to BSA was considered to involve primarily the phenyl group.	Phenylbutazone	15-17	albumin	Homo sapiens	21-24
2540249-3	1989	Compared to controls, CVF- and PB-treated animals killed when the neutrophil infiltration started (32 h) had a significantly reduced neutrophil infiltration, as measured by kidney MPO activity.	Phenylbutazone	31-33	myeloperoxidase	Rattus norvegicus	180-183
3446289-3	1987	By contrast, phenylbutazone (below 100 micrograms/ml) only altered the directed PMN migration induced by FMLP, in two characteristic ways: by impairing the optimal response to 10(-7) M FMLP, and in particular, by restoring the loss of migration induced by higher but deactivating concentrations of 10(-6) and 10(-5) M. Indomethacin had similar effects to those of phenylbutazone on FMLP-induced PMN migration and in addition slightly impaired spontaneous PMN migration.	Phenylbutazone	13-27	formyl peptide receptor 1	Homo sapiens	105-109
2441927-5	1987	An example is shown in which this method permits the verification that two drugs (phenylbutazone and azapropazone) are both bound by the same high- and low-affinity sites of a protein (alpha-fetoprotein).	Phenylbutazone	82-96	alpha fetoprotein	Homo sapiens	185-202
3304389-3	1987	The results support the concept that CLL/MLL is a condition of multiple aetiologies with evidence for genetic predisposition through an excess of family cases, immune perturbation demonstrated by excessive previous skin diseases and phenylbutazone use, and viral involvement shown by links with infectious diseases and multiple sclerosis.	Phenylbutazone	233-247	lysine methyltransferase 2A	Homo sapiens	41-44
3446289-3	1987	By contrast, phenylbutazone (below 100 micrograms/ml) only altered the directed PMN migration induced by FMLP, in two characteristic ways: by impairing the optimal response to 10(-7) M FMLP, and in particular, by restoring the loss of migration induced by higher but deactivating concentrations of 10(-6) and 10(-5) M. Indomethacin had similar effects to those of phenylbutazone on FMLP-induced PMN migration and in addition slightly impaired spontaneous PMN migration.	Phenylbutazone	13-27	formyl peptide receptor 1	Homo sapiens	185-189
3446289-3	1987	By contrast, phenylbutazone (below 100 micrograms/ml) only altered the directed PMN migration induced by FMLP, in two characteristic ways: by impairing the optimal response to 10(-7) M FMLP, and in particular, by restoring the loss of migration induced by higher but deactivating concentrations of 10(-6) and 10(-5) M. Indomethacin had similar effects to those of phenylbutazone on FMLP-induced PMN migration and in addition slightly impaired spontaneous PMN migration.	Phenylbutazone	13-27	formyl peptide receptor 1	Homo sapiens	185-189
3446289-3	1987	By contrast, phenylbutazone (below 100 micrograms/ml) only altered the directed PMN migration induced by FMLP, in two characteristic ways: by impairing the optimal response to 10(-7) M FMLP, and in particular, by restoring the loss of migration induced by higher but deactivating concentrations of 10(-6) and 10(-5) M. Indomethacin had similar effects to those of phenylbutazone on FMLP-induced PMN migration and in addition slightly impaired spontaneous PMN migration.	Phenylbutazone	364-378	formyl peptide receptor 1	Homo sapiens	105-109
3446289-5	1987	Of the three drugs, phenylbutazone and indomethacin also impaired FMLP-induced changes in the shape of PMN.	Phenylbutazone	20-34	formyl peptide receptor 1	Homo sapiens	66-70
20144114-4	1987	The results of this study are as follows: The drugs, phenylbutazone, indomethacin and acetyl-salicylic acid, are effective, when they are administered at the initial phase of inflammation, while in the chronic phase the effects of them are variable, though significant in patients whose PSP clearance rate is below 45 per cent.	Phenylbutazone	53-67	microseminoprotein beta	Homo sapiens	287-290
3917545-6	1985	Chromatographic analysis of the metabolism of 14C-labeled arachidonic acid in this system revealed that PB-dependent inactivation of PHS is markedly increased in the presence of 100 microM H2O2.	Phenylbutazone	104-106	pterin-4 alpha-carbinolamine dehydratase 1	Homo sapiens	133-136
3094043-2	1986	While the COX inhibitors diclofenac-Na and acetylsalicylic acid in combination with PLA2 and LOX inhibitors mostly gave overadditive antiinflammatory effects in the carrageenin edema, phenylbutazone in combination at most displayed additivity.	Phenylbutazone	184-198	phospholipase A2 group IB	Rattus norvegicus	84-88
2996321-13	1985	The strongest inhibitory effect was that of phenylbutazone on fMLP-stimulated cells.	Phenylbutazone	44-58	formyl peptide receptor 1	Homo sapiens	62-66
3997320-1	1985	The selective in vitro release of lysozyme from human monocytes and granulocytes was not greatly influenced by temperatures above 37 degrees C and up to 40 degrees C. The release was markedly inhibited by preincubation with phenylbutazone, oxyphenylbutazone, colchicine and vincristine.	Phenylbutazone	224-238	lysozyme	Homo sapiens	34-42
3917545-0	1985	Inactivation of prostaglandin H synthase and prostacyclin synthase by phenylbutazone.	Phenylbutazone	70-84	pterin-4 alpha-carbinolamine dehydratase 1	Homo sapiens	16-40
3917545-0	1985	Inactivation of prostaglandin H synthase and prostacyclin synthase by phenylbutazone.	Phenylbutazone	70-84	prostaglandin I2 synthase	Homo sapiens	45-66
3917545-2	1985	Phenylbutazone (PB), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS).	Phenylbutazone	0-14	pterin-4 alpha-carbinolamine dehydratase 1	Homo sapiens	125-149
3917545-2	1985	Phenylbutazone (PB), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS).	Phenylbutazone	0-14	pterin-4 alpha-carbinolamine dehydratase 1	Homo sapiens	151-154
3917545-2	1985	Phenylbutazone (PB), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS).	Phenylbutazone	16-18	pterin-4 alpha-carbinolamine dehydratase 1	Homo sapiens	125-149
3718179-2	1986	In vitro quantification of the interactions of phenprocoumon, warfarin and methylsulfinyl warfarin with phenylbutazone on human serum albumin].	Phenylbutazone	104-118	albumin	Homo sapiens	134-141
3295745-7	1986	LIF production of lymphocytes was inhibited by INDO, ASA, PhB, CHINOIN 127 and CHINOIN 105.	Phenylbutazone	58-61	LIF interleukin 6 family cytokine	Homo sapiens	0-3
4042014-10	1985	The nonsteroidal anti-inflammatory drugs produced a reverse type I binding spectrum with oxidized cytochrome P-450; indomethacin and phenylbutazone were the strongest ligands.	Phenylbutazone	133-147	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	98-114
3917545-2	1985	Phenylbutazone (PB), a nonsteroidal anti-inflammatory drug, is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS).	Phenylbutazone	16-18	pterin-4 alpha-carbinolamine dehydratase 1	Homo sapiens	151-154
6440614-6	1984	In this new multiple-site model the potent lipoxygenase inhibitors (e.g. acetone phenylhydrazone, phenidone) possess high affinities for both sites, whereas weak inhibitors and certain cyclo-oxygenase inhibitors (e.g. benoxaprofen, phenylbutazone, indomethacin) interact predominantly with the supplementary site on the lipoxygenase but lack affinity for the catalytic site.	Phenylbutazone	232-246	linoleate 9S-lipoxygenase-4	Glycine max	43-55
6482089-9	1984	Other anti-inflammatory agents including aspirin, sodium salicylate, phenylbutazone and prednisolone were found to be poorly or scarcely inhibitory for both cathepsins B and H.	Phenylbutazone	69-83	cathepsin B	Rattus norvegicus	157-175
6086524-3	1984	Superoxide release induced by FMLP was inhibited by all three drugs with half-maximal inhibition (KI50) at 2.5, 30, and 120 microM for sulfinpyrazone, phenylbutazone, and indomethacin, respectively.	Phenylbutazone	151-165	formyl peptide receptor 1	Homo sapiens	30-34
6086524-5	1984	The neutrophil"s response to NaF was blunted by sulfinpyrazone (KI50 = 400 microM) and phenylbutazone (KI50 = 65 microM), but was unaffected by indomethacin.	Phenylbutazone	87-101	C-X-C motif chemokine ligand 8	Homo sapiens	29-32
3917545-8	1985	Prostacyclin synthase is even more sensitive to inactivation by the combined PB and H2O2 treatment, with a corresponding half-maximal effect at PB concentrations near 25 microM.	Phenylbutazone	77-79	prostaglandin I2 synthase	Homo sapiens	0-21
3917545-8	1985	Prostacyclin synthase is even more sensitive to inactivation by the combined PB and H2O2 treatment, with a corresponding half-maximal effect at PB concentrations near 25 microM.	Phenylbutazone	144-146	prostaglandin I2 synthase	Homo sapiens	0-21
3917545-9	1985	This PB- and H2O2-dependent inactivation is demonstrable whether PGH2 is generated in situ from arachidonic acid or is added exogenously, supporting a direct effect of the treatment on prostacyclin synthase.	Phenylbutazone	5-7	prostaglandin I2 synthase	Homo sapiens	185-206
3917545-10	1985	As PB undergoes peroxide-dependent co-oxygenation catalyzed by PHS, we propose that it is an oxygenated derivative of PB, rather than the parent compound, which is responsible for the inactivation of PHS and prostacyclin synthase.	Phenylbutazone	3-5	pterin-4 alpha-carbinolamine dehydratase 1	Homo sapiens	63-66
3917545-10	1985	As PB undergoes peroxide-dependent co-oxygenation catalyzed by PHS, we propose that it is an oxygenated derivative of PB, rather than the parent compound, which is responsible for the inactivation of PHS and prostacyclin synthase.	Phenylbutazone	3-5	pterin-4 alpha-carbinolamine dehydratase 1	Homo sapiens	200-203
3917545-10	1985	As PB undergoes peroxide-dependent co-oxygenation catalyzed by PHS, we propose that it is an oxygenated derivative of PB, rather than the parent compound, which is responsible for the inactivation of PHS and prostacyclin synthase.	Phenylbutazone	3-5	prostaglandin I2 synthase	Homo sapiens	208-229
3917545-10	1985	As PB undergoes peroxide-dependent co-oxygenation catalyzed by PHS, we propose that it is an oxygenated derivative of PB, rather than the parent compound, which is responsible for the inactivation of PHS and prostacyclin synthase.	Phenylbutazone	118-120	pterin-4 alpha-carbinolamine dehydratase 1	Homo sapiens	63-66
3917545-10	1985	As PB undergoes peroxide-dependent co-oxygenation catalyzed by PHS, we propose that it is an oxygenated derivative of PB, rather than the parent compound, which is responsible for the inactivation of PHS and prostacyclin synthase.	Phenylbutazone	118-120	pterin-4 alpha-carbinolamine dehydratase 1	Homo sapiens	200-203
3917545-10	1985	As PB undergoes peroxide-dependent co-oxygenation catalyzed by PHS, we propose that it is an oxygenated derivative of PB, rather than the parent compound, which is responsible for the inactivation of PHS and prostacyclin synthase.	Phenylbutazone	118-120	prostaglandin I2 synthase	Homo sapiens	208-229
6143813-1	1984	Modifications in prolactin specific binding in the rat liver induced by different non-steroidal anti-inflammatory drugs (indomethacin, piroxicam, ketoprofen, phenylbutazone, mefenamic acid and acetylsalicylic acid) have been studied.	Phenylbutazone	158-172	prolactin	Rattus norvegicus	17-26
6622513-4	1983	Experiments to determine the mechanism for the inhibition of lipoprotein lipase suggest that it may be related to non-specific binding of the drug to the enzyme since other drugs e.g., phenylbutazone and a coumarin derivative which bind non-specifically to serum albumin showed similar inhibitory activity.	Phenylbutazone	185-199	lipase G, endothelial type	Rattus norvegicus	73-79
6756410-1	1982	Phenylbutazone (PBZ) is known to inhibit the oriented migration of human polymorphonuclear leukocytes (PMNs) induced by formyl-methionyl-leucyl-phenylalanine (FMLP), and to protect these cells against the deactivation caused by their prior incubation with FMLP.	Phenylbutazone	0-14	formyl peptide receptor 1	Homo sapiens	159-163
6756410-1	1982	Phenylbutazone (PBZ) is known to inhibit the oriented migration of human polymorphonuclear leukocytes (PMNs) induced by formyl-methionyl-leucyl-phenylalanine (FMLP), and to protect these cells against the deactivation caused by their prior incubation with FMLP.	Phenylbutazone	0-14	formyl peptide receptor 1	Homo sapiens	256-260
6756410-1	1982	Phenylbutazone (PBZ) is known to inhibit the oriented migration of human polymorphonuclear leukocytes (PMNs) induced by formyl-methionyl-leucyl-phenylalanine (FMLP), and to protect these cells against the deactivation caused by their prior incubation with FMLP.	Phenylbutazone	16-19	formyl peptide receptor 1	Homo sapiens	159-163
6756410-1	1982	Phenylbutazone (PBZ) is known to inhibit the oriented migration of human polymorphonuclear leukocytes (PMNs) induced by formyl-methionyl-leucyl-phenylalanine (FMLP), and to protect these cells against the deactivation caused by their prior incubation with FMLP.	Phenylbutazone	16-19	formyl peptide receptor 1	Homo sapiens	256-260
6756410-6	1982	PBZ inhibited both the oriented migration and locomotion speed induced by 10(-7) M FMLP, but did not affect its chemotactic activity.	Phenylbutazone	0-3	formyl peptide receptor 1	Homo sapiens	83-87
6756410-9	1982	These results demonstrate that PBZ modulates the chemokinetic effect of FMLP on PMNs and thus alters oriented PMN migration.	Phenylbutazone	31-34	formyl peptide receptor 1	Homo sapiens	72-76
7205544-4	1980	In the acute exudative stage of this inflammation, a single oral administration of dexamethasone, indomethacin, phenylbutazone or aspirin all exerted potent anti-exudative effect, while in the chronic proliferative stage, only dexamethasone was effective in inhibiting the exudation of the labeled albumin.	Phenylbutazone	112-126	albumin	Rattus norvegicus	298-305
7250148-1	1981	Phenylbutazone suppresses the C-6 hydroxylation, absorption rate, bioavailability, and renal and plasma clearancee rates of dexamethasone administered orally to normal and oedemateous rats.	Phenylbutazone	0-14	complement C6	Rattus norvegicus	30-33
7252092-5	1981	TFp of phenylbutazone was 25.83 per cent +/- 0.46, of oxyphenylbutazone 22.48 per cent +/- 1.38, of ketoprofene 35.574 per cent +/- 0.95 and of indomethacin 36.19 per cent +/- 0.26.	Phenylbutazone	7-21	inhibitor of carbonic anhydrase pseudogene	Homo sapiens	0-3
6105183-3	1980	Chloride ions, phenylbutazone and acenocoumarin seem to displace phenprocoumon from its primary binding site on human serum albumin.	Phenylbutazone	15-29	albumin	Bos taurus	118-131
6291348-10	1982	The most potent NSAIDs against MPO-CL were BW755C, phenylbutazone, indomethacin and sulindac sulfide.	Phenylbutazone	51-65	myeloperoxidase	Homo sapiens	31-34
7107079-3	1982	Plasma phenylbutazone half-life (t1/2 beta) was shortened significantly (p less than 0.05) in the cigarette smokers as compared to the non-smoker control group.	Phenylbutazone	7-21	interleukin 1 receptor like 1	Homo sapiens	33-42
59505-4	1976	In the early purpuric lesions from 6 patients with Schonlein-Henoch syndrome and from a patient with diseeminated vascular coagulation from acute allergic reaction to phenylbutazone, deposits of fibrinogen occurred mainly in the vessel walls.	Phenylbutazone	167-181	fibrinogen beta chain	Homo sapiens	195-205
467465-3	1979	Palmitic acid and some acidic drugs, warfarin and phenylbutazone added to human serum albumin, decreased phenytoin binding in a non competitive way.	Phenylbutazone	50-64	albumin	Homo sapiens	80-93
358750-7	1978	Phenylbutazone reduced the effect of sodium azide on leukocyte chemiluminescnece, indicating that the drug might also inhibit myeloperoxidase dependent chemiluminescnece.	Phenylbutazone	0-14	myeloperoxidase	Homo sapiens	126-141
665123-1	1978	The effect of acute parenteral and chronic oral administration of lysine-acetylsalicylate and phenylbutazone on fasting and meal-stimulated serum gastrin levels was investigated in healthy volunteers.	Phenylbutazone	94-108	gastrin	Homo sapiens	146-153
669905-0	1978	The binding of phenylbutazone to bovine and horse serum albumin.	Phenylbutazone	15-29	albumin	Bos taurus	50-63
277090-4	1978	Ad 3) Histologically, and to some extent clinically, hepatocellular (e.g. propylthiouracil) may be distinguished from cholestatic (e.g. tolbutamide) reactions, but overlapping (e.g. phenylbutazone) and individual variations are common.	Phenylbutazone	182-196	presenilin 1	Homo sapiens	0-4
913025-5	1977	It is suggested that phenylbutazone and oxyphenbutazone act by inducing form of cytochrome P-450 with low activity for tolbutamide hydroxylation, whereas sulfaphenazole acts by direct inhibition of the microsomal mixed function oxidase system.	Phenylbutazone	21-35	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-96
930756-1	1977	The anti-inflammatory agents, phenylbutazone, naproxen and niflumic acid inhibited in vitro rabbit peritoneal neutrophil chemotactic responsiveness to Escherichia coli derived chemotactic factor/s when added to cells suspended in 0.1% bovine serum albumin (BSA).	Phenylbutazone	30-44	albumin	Oryctolagus cuniculus	242-255
863908-5	1977	The binding properties of the HSA derivatives have been tested with bilirubin, diazepam (a benzodiazepine drug), phenylbutazone, and indomethacin by circular dichroism.	Phenylbutazone	113-127	albumin	Homo sapiens	30-33
897766-0	1977	[Dynamic changes of lysozyme concentration in the blood serum in patients with typhoid fever treated levomycetin in conjunction with prednisolone and butadione].	Phenylbutazone	150-159	lysozyme	Homo sapiens	20-28
1026974-0	1976	Effect of bendazac and phenylbutazone on polymerization of bovine serum albumin.	Phenylbutazone	23-37	albumin	Homo sapiens	66-79
959670-3	1976	In-vitro hepatic microsomal metabolism of warfarin and cytochrome P-450 content were greater for hepatic microsomes derived from phenylbutazone pretreated animals.	Phenylbutazone	129-143	Cytochrome P450 1A1	Canis lupus familiaris	55-71
575299-2	1979	The binding affinity of fluorescein and of phenylbutazone to human serum albumin (HSA) and to bovine serum albumin (BSA), respectively, as well as of the two drugs together to each protein in dilute aqueous solution has been studied by means of gel permeation chromatography, circular dichroism, U.V.	Phenylbutazone	43-57	albumin	Homo sapiens	67-80
575299-2	1979	The binding affinity of fluorescein and of phenylbutazone to human serum albumin (HSA) and to bovine serum albumin (BSA), respectively, as well as of the two drugs together to each protein in dilute aqueous solution has been studied by means of gel permeation chromatography, circular dichroism, U.V.	Phenylbutazone	43-57	albumin	Homo sapiens	101-114
1148923-2	1975	In adjuvant arthritis, haptoglobin, seromucoid, and chiefly orosomucoid serum levels were generally very sensitive to anti-inflammatory agents such as phenylbutazone and pyridinol carbamate, and to immunosuppressive agents such as L-asparaginase.	Phenylbutazone	151-165	haptoglobin	Rattus norvegicus	23-34
4799079-2	1973	Drugs such as phenobarbitone and phenylbutazone, which increase the concentration of microsomal haem and cytochrome P-450, also increase the saturation of rat liver apo-(tryptophan pyrrolase) with its haem activator, as does the haem precursor 5-aminolaevulinate.	Phenylbutazone	33-47	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	105-121
234834-0	1975	Correlation of aryl hydrocarbon hydroxylase activity of human lymphocyte cultures and plasma elimination rates for antipyrine and phenylbutazone.	Phenylbutazone	130-144	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	15-43
234834-1	1975	A high correlation was observed between the aryl hydrocarbon hydroxylase activities in short-term lymphocyte cultures of 23 individuals and their plasma half-lives of antipyrine and phenylbutazone.	Phenylbutazone	182-196	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	44-72
234834-2	1975	Individuals with low inducibility of aryl hydrocarbon hydroxylase activities had very long plasma half-lives of antipyrine and phenylbutazone, whereas subjects with high inducibility of aryl hydrocarbon hydroxylase activites had relatively short plasma half-lives.	Phenylbutazone	127-141	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	37-65
4374676-0	1974	Effects of phenylbutazone on the activities of cathepsin D, collagenolytic cathepsin and collagen peptidase in turpentine-induced granuloma.	Phenylbutazone	11-25	cathepsin D	Homo sapiens	47-58
4799079-2	1973	Drugs such as phenobarbitone and phenylbutazone, which increase the concentration of microsomal haem and cytochrome P-450, also increase the saturation of rat liver apo-(tryptophan pyrrolase) with its haem activator, as does the haem precursor 5-aminolaevulinate.	Phenylbutazone	33-47	tryptophan 2,3-dioxygenase	Rattus norvegicus	170-190
4268896-5	1973	The effect of plasmin on platelets was inhibited by soybean trypsin inhibitor, epsilon aminocaproic acid, Persantin, prostaglandin E(1), and phenylbutazone.	Phenylbutazone	141-155	plasminogen	Homo sapiens	14-21
13294099-0	1955	[Relation of butazolidine to heparin and the antiheparin factor of ACTH preparations].	Phenylbutazone	13-25	proopiomelanocortin	Homo sapiens	67-71
4105907-1	1971	V. The interaction of phenylbutazone, flufenamic acid, and dicoumarol with acetylsalicylic acid-treated human serum albumin.	Phenylbutazone	22-36	albumin	Homo sapiens	110-123
14263924-0	1964	XANTHINE DEHYDROGENASE OF HUMAN LIVER AND ITS INHIBITION BY COLCHICINE AND PHENYLBUTAZONE.	Phenylbutazone	75-89	xanthine dehydrogenase	Homo sapiens	0-22
13634834-0	1959	[C-reactive protein in typhoid treated with combined chloramphenicol & phenylbutazone].	Phenylbutazone	75-89	C-reactive protein	Homo sapiens	1-19
13388739-0	1956	[Effect of somatotropin on ulcerogenous phenomena of phenylbutazone].	Phenylbutazone	53-67	growth hormone 1	Homo sapiens	11-23
13365579-0	1956	[The relation of butazolidines to heparin and the anti-heparin factor of ACTH preparations].	Phenylbutazone	17-30	proopiomelanocortin	Homo sapiens	73-77
13365580-0	1956	[The relation of butazolidines to heparin and the anti-heparin factor of ACTH preparations].	Phenylbutazone	17-30	proopiomelanocortin	Homo sapiens	73-77
33264700-8	2021	Its applicability was finally demonstrated on the determination of apparent binding parameters of bovine serum albumin for basic drugs propranolol and lidocaine and acid drug phenylbutazone.	Phenylbutazone	175-189	albumin	Homo sapiens	105-118